Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A novel hierarchical prognostic model of AML solely based on molecular mutations.
Grossmann V, Schnittger S, Kohlmann A, Eder C, Roller A, Dicker F, Schmid C, Wendtner CM, Staib P, Serve H, Kreuzer KA, Kern W, Haferlach T, Haferlach C. Grossmann V, et al. Among authors: eder c. Blood. 2012 Oct 11;120(15):2963-72. doi: 10.1182/blood-2012-03-419622. Epub 2012 Aug 20. Blood. 2012. PMID: 22915647 Free article.
Landscape of TET2 mutations in acute myeloid leukemia.
Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, Dicker F, Fasan A, Haferlach C, Haferlach T, Kern W, Schnittger S, Kohlmann A. Weissmann S, et al. Among authors: eder c. Leukemia. 2012 May;26(5):934-42. doi: 10.1038/leu.2011.326. Epub 2011 Nov 25. Leukemia. 2012. PMID: 22116554
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.
Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, Kohlmann A, Illig T, Klopp N, Wichmann HE, Kreuzer KA, Schmid C, Staib P, Peceny R, Schmitz N, Kern W, Haferlach C, Haferlach T. Schnittger S, et al. Among authors: eder c. Leukemia. 2013 Jan;27(1):82-91. doi: 10.1038/leu.2012.262. Epub 2012 Sep 11. Leukemia. 2013. PMID: 23018865
The role of different genetic subtypes of CEBPA mutated AML.
Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C, Weissmann S, Dicker F, Kohlmann A, Schindela S, Kern W, Haferlach T, Schnittger S. Fasan A, et al. Among authors: eder c. Leukemia. 2014 Apr;28(4):794-803. doi: 10.1038/leu.2013.273. Epub 2013 Sep 23. Leukemia. 2014. PMID: 24056881
BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia.
Weber S, Alpermann T, Dicker F, Jeromin S, Nadarajah N, Eder C, Fasan A, Kohlmann A, Meggendorfer M, Haferlach C, Kern W, Haferlach T, Schnittger S. Weber S, et al. Among authors: eder c. Blood Cancer J. 2014 Jan 10;4(1):e173. doi: 10.1038/bcj.2013.71. Blood Cancer J. 2014. PMID: 24413067 Free PMC article.
A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls.
Schnittger S, Bacher U, Eder C, Lohse P, Haferlach C, Kern W, Haferlach T. Schnittger S, et al. Among authors: eder c. Exp Hematol. 2011 Jan;39(1):87-94. doi: 10.1016/j.exphem.2010.09.009. Epub 2010 Oct 1. Exp Hematol. 2011. PMID: 20888888
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).
Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V, Kohlmann A, Alpermann T, Yoshida K, Ogawa S, Koeffler HP, Kern W, Haferlach C, Schnittger S. Meggendorfer M, et al. Among authors: eder c. Blood. 2012 Oct 11;120(15):3080-8. doi: 10.1182/blood-2012-01-404863. Epub 2012 Aug 23. Blood. 2012. PMID: 22919025 Free PMC article.
196 results